NCT06122415View on ClinicalTrials.gov

The Swedish BioFINDER - Memory Clinic Study

RecruitingOBSERVATIONAL
Enrollment

1,200

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Mild DementiaMild Cognitive ImpairmentSCDAlzheimer DiseaseLewy Body DiseaseFrontotemporal DegenerationVascular Dementia
Interventions
DIAGNOSTIC_TEST

Plasma Amyloid Probability Score 2 (APS 2) score

APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.

DIAGNOSTIC_TEST

Plasma ptau217/nptau217

The cut off will be predefined. The samples will be analysed prospectively every two weeks.

DIAGNOSTIC_TEST

Plasma ptau217

The cut off will be predefined. The samples will be analysed prospectively every two weeks.

DIAGNOSTIC_TEST

Plasma neurofilament light (NfL)

The cut off will be predefined. The samples will be analysed prospectively every two weeks.

DIAGNOSTIC_TEST

Plasma Ab42/Ab40

The cut off will be predefined. The samples will be analysed prospectively every two weeks.

Trial Locations (1)

Unknown

RECRUITING

Skåne University Hospital, Malmo

All Listed Sponsors
collaborator

Lund University

OTHER

lead

Skane University Hospital

OTHER